Trending Now
Ovid Therapeutics Inc (NASDAQ:OVID) Says the Phase 2 ELEKTRA study of...
Today, there are hundreds of thousands of people struggling with different rare neurological diseases. This is what pushed Ovid Therapeutics Inc (NASDAQ:OVID) into initiating...
DIH Holding US, Inc. (DHAI): Pioneering Rehabilitation with Cutting-Edge Technology
Let’s talk about something truly inspiring: the future of rehabilitation. On December 23, 2024, DIH Holding US, Inc. (NASDAQ: DHAI) announced...
Predictive Oncology Inc. (Nasdaq: POAI): A Transformative Acquisition by Renovaro Inc.
The biotechnological domain is currently abuzz with developments surrounding the acquisition of Predictive Oncology Inc. (Nasdaq: POAI) by Renovaro Inc. (Nasdaq: RENB)....
Popular News
Jaguar Health Inc. (NASDAQ:JAGX) Commences Phase 3 Of Crofelemer Study In...
Jaguar Health Inc. (NASDAQ:JAGX) has announced that its wholly-owned subsidiary, Napo Pharmaceuticals Inc., has commenced a vital third phase crofelemer (Mytesi®) study, The trial...
MAKE IT MODERN
LATEST REVIEWS
Inhibrx Inc. (NASDAQ: INBX) Reports Promising INBRX-101 Safety and Pharmacokinetics Results...
Inhibrx Inc. (NASDAQ: INBX) has announced preliminary findings from the phase 1 clinical study evaluating INBRX-101 pharmacokinetics and safety in alpha-1 antitrypsin deficiency (AATD)...
MAKE IT MODERN
PERFORMANCE TRAINING
A Snapshot Of Eyepoint Pharmaceuticals Inc’s (NASDAQ:EYPT) Performance In Q3 2020 Ahead Of 3Q...
Eyepoint Pharmaceuticals Inc (NASDAQ:EYPT) is slated to release its Q3 2020 financial and operational results, but it also recently released its Q3 performance highlights...
Heat Biologics Inc. (NASDAQ:HTBX) Receives Investigational New Drug Application Approval From The FDA For...
Heat Biologics Inc. (NASDAQ:HTBX) has announced that it has received FDA clearance for the Investigational New Drug application for PTX-35, which is developed by...
PDS Biotechnology Corporation’s (NASDAQ: PDS) VERSATILE-002 Study in advanced HPV-related Head and Neck Cancer...
PDS Biotechnology Corporation (NASDA: PDS) has announced that its VERSATILE-002 second phase study of advanced human papillomavirus (HPV)-related head and neck cancer treatment attained...
Atossa Therapeutics Inc (NASDAQ:ATOS) Commences Treatment Of A Patient With Ovarian Cancer Using Its...
Atossa Therapeutics Inc (NASDAQ:ATOS) began treating an ovarian cancer patient with its oral Endoxifen under an expanded pathway permitted previously by the US FDA.
Surgeon-in-Chief,...
Diffusion Pharmaceuticals Inc (NASDAQ:DFFN) Submits IND filing For TSC In Preparation For Phase 1b/2b...
Diffusion Pharmaceuticals Inc (NASDAQ:DFFN) recently announced that it submitted an Investigational New Drug (IND) application filing to the Food and Drug Administration for trans...
MAKE IT MODERN
